Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields

Amid market turbulence, three high-yielding healthcare stocks exhibit varied outlooks: Dentsply Sirona (XRAY, 4.62% yield) received mixed analyst ratings and price target cuts despite strong Q2 results; Bristol-Myers Squibb (BMY, 5.15% yield) saw negative analyst revisions despite an FDA Breakthrough designation; however, Medtronic (MDT, 3.06% yield) garnered positive analyst upgrades and price target increases after exceeding Q1 earnings and announcing board changes post-Elliott Management engagement, signaling potential strategic improvements.

Analysis

An examination of three high-yield healthcare stocks reveals divergent analyst outlooks despite generally positive corporate news. Dentsply Sirona (XRAY), with a 4.62% yield, reported a beat on second-quarter EPS and sales, yet analysts at both UBS and Stifel responded by cutting their price targets, suggesting underlying concerns may be outweighing the strong quarterly performance. Similarly, Bristol-Myers Squibb (BMY), offering the highest yield at 5.15%, secured a significant FDA Breakthrough Therapy Designation for a key drug candidate, but this positive pipeline development was overshadowed by price target reductions from Citigroup and Morgan Stanley, with the latter maintaining an Underweight rating. This suggests analysts are discounting the near-term value of the designation or have broader concerns. In contrast, Medtronic (MDT) presents a more cohesive and bullish narrative; its 3.06% yield is supported by a first-quarter earnings beat, positive analyst actions including price target increases from Mizuho and Citigroup, and new board appointments following engagement with activist investor Elliott Management, signaling potential for strategic and operational improvements.

Key Decisions for Investors

• Investors may find Medtronic (MDT) to be the most compelling investment of the three, as its combination of an earnings beat, positive analyst revisions, and activist-driven governance changes suggests strong fundamental momentum and potential for capital appreciation.
• The high yields of Bristol-Myers Squibb (BMY) and Dentsply Sirona (XRAY) should be viewed with caution, as the consistent analyst price target cuts despite positive news headlines signal that the market may be pricing in future headwinds not immediately apparent.
• Deeper due diligence is warranted for BMY and XRAY to understand the disconnect between positive operational or clinical news and bearish analyst sentiment, focusing on potential risks to their long-term cash flow generation capabilities.